CR20170090A - Derivados de terahidroquinolina como inhibidores del bromodominio - Google Patents
Derivados de terahidroquinolina como inhibidores del bromodominioInfo
- Publication number
- CR20170090A CR20170090A CR20170090A CR20170090A CR20170090A CR 20170090 A CR20170090 A CR 20170090A CR 20170090 A CR20170090 A CR 20170090A CR 20170090 A CR20170090 A CR 20170090A CR 20170090 A CR20170090 A CR 20170090A
- Authority
- CR
- Costa Rica
- Prior art keywords
- terahydroquinoline
- bromodominum
- inhibitors
- derivatives
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a nuevos compuestos, a composiciones farmacéuticas que contienen tales compuestos y a su uso en terapia
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049449P | 2014-09-12 | 2014-09-12 | |
| PCT/EP2015/070665 WO2016038120A1 (en) | 2014-09-12 | 2015-09-09 | Tetrahydroquinoline derivatives as bromodomain inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20170090A true CR20170090A (es) | 2017-05-08 |
Family
ID=54065889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20170090A CR20170090A (es) | 2014-09-12 | 2015-09-09 | Derivados de terahidroquinolina como inhibidores del bromodominio |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US10059699B2 (es) |
| EP (1) | EP3191476B1 (es) |
| JP (1) | JP6531167B2 (es) |
| KR (1) | KR20170054421A (es) |
| CN (1) | CN106687453B (es) |
| AR (1) | AR101806A1 (es) |
| AU (1) | AU2015314184B2 (es) |
| BR (1) | BR112017004580A2 (es) |
| CA (1) | CA2958159A1 (es) |
| CL (1) | CL2017000587A1 (es) |
| CO (1) | CO2017001601A2 (es) |
| CR (1) | CR20170090A (es) |
| CY (1) | CY1121369T1 (es) |
| DK (1) | DK3191476T3 (es) |
| DO (1) | DOP2017000058A (es) |
| EA (1) | EA031679B9 (es) |
| ES (1) | ES2705623T3 (es) |
| HR (1) | HRP20182064T1 (es) |
| HU (1) | HUE041694T2 (es) |
| IL (1) | IL250397A0 (es) |
| LT (1) | LT3191476T (es) |
| MA (1) | MA40366A (es) |
| MX (1) | MX373845B (es) |
| PE (1) | PE20170675A1 (es) |
| PH (1) | PH12017500348A1 (es) |
| PL (1) | PL3191476T3 (es) |
| PT (1) | PT3191476T (es) |
| RS (1) | RS58135B1 (es) |
| SG (1) | SG11201701043UA (es) |
| SI (1) | SI3191476T1 (es) |
| SM (1) | SMT201900019T1 (es) |
| TR (1) | TR201820050T4 (es) |
| TW (1) | TWI686389B (es) |
| UY (1) | UY36292A (es) |
| WO (1) | WO2016038120A1 (es) |
| ZA (1) | ZA201700883B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029052B1 (ru) | 2013-03-14 | 2018-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с |
| HUE047208T2 (hu) | 2014-09-12 | 2020-04-28 | Boehringer Ingelheim Int | A katepszin-C spirociklikus inhibitorai |
| US11028051B2 (en) * | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| EP3873474A4 (en) | 2018-10-30 | 2022-07-13 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS |
| JP7465945B2 (ja) | 2019-07-02 | 2024-04-11 | ニューベイション・バイオ・インコーポレイテッド | Ｂｅｔ阻害剤としてのヘテロ環式化合物 |
| EP4095128A1 (en) | 2021-05-25 | 2022-11-30 | Centre national de la recherche scientifique | Tetrahydroquinoline (thq) coumpounds |
| US12527741B2 (en) | 2021-06-17 | 2026-01-20 | Wisconsin Alumni Research Foundation | Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19 |
| CN116919963B (zh) * | 2023-07-28 | 2025-09-12 | 浙江大学 | 一种基于水网络策略的溴结构域蛋白4活性化合物的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010113498A1 (ja) * | 2009-03-31 | 2010-10-07 | 興和株式会社 | テトラヒドロキノリン化合物を有効成分とする貧血の予防及び／又は治療剤 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| CN105189461B (zh) * | 2013-03-14 | 2018-05-15 | 葛兰素史克知识产权第二有限公司 | 2,3-二取代的1-酰基-4-氨基-1,2,3,4-四氢喹啉衍生物和它们作为溴结构域抑制剂的用途 |
-
2015
- 2015-09-09 WO PCT/EP2015/070665 patent/WO2016038120A1/en not_active Ceased
- 2015-09-09 HU HUE15760461A patent/HUE041694T2/hu unknown
- 2015-09-09 DK DK15760461.2T patent/DK3191476T3/en active
- 2015-09-09 MX MX2017003219A patent/MX373845B/es active IP Right Grant
- 2015-09-09 BR BR112017004580-0A patent/BR112017004580A2/pt not_active Application Discontinuation
- 2015-09-09 MA MA040366A patent/MA40366A/fr unknown
- 2015-09-09 PE PE2017000388A patent/PE20170675A1/es unknown
- 2015-09-09 EA EA201790484A patent/EA031679B9/ru not_active IP Right Cessation
- 2015-09-09 CR CR20170090A patent/CR20170090A/es unknown
- 2015-09-09 SG SG11201701043UA patent/SG11201701043UA/en unknown
- 2015-09-09 US US15/509,894 patent/US10059699B2/en active Active
- 2015-09-09 TR TR2018/20050T patent/TR201820050T4/tr unknown
- 2015-09-09 SI SI201530529T patent/SI3191476T1/sl unknown
- 2015-09-09 PT PT15760461T patent/PT3191476T/pt unknown
- 2015-09-09 HR HRP20182064TT patent/HRP20182064T1/hr unknown
- 2015-09-09 RS RS20190001A patent/RS58135B1/sr unknown
- 2015-09-09 SM SM20190019T patent/SMT201900019T1/it unknown
- 2015-09-09 AU AU2015314184A patent/AU2015314184B2/en not_active Ceased
- 2015-09-09 ES ES15760461T patent/ES2705623T3/es active Active
- 2015-09-09 KR KR1020177008675A patent/KR20170054421A/ko not_active Withdrawn
- 2015-09-09 CN CN201580048713.8A patent/CN106687453B/zh not_active Expired - Fee Related
- 2015-09-09 JP JP2017513723A patent/JP6531167B2/ja not_active Expired - Fee Related
- 2015-09-09 LT LTEP15760461.2T patent/LT3191476T/lt unknown
- 2015-09-09 CA CA2958159A patent/CA2958159A1/en not_active Abandoned
- 2015-09-09 EP EP15760461.2A patent/EP3191476B1/en active Active
- 2015-09-09 PL PL15760461T patent/PL3191476T3/pl unknown
- 2015-09-10 AR ARP150102888A patent/AR101806A1/es unknown
- 2015-09-10 UY UY0001036292A patent/UY36292A/es not_active Application Discontinuation
- 2015-09-10 TW TW104129977A patent/TWI686389B/zh not_active IP Right Cessation
-
2017
- 2017-02-01 IL IL250397A patent/IL250397A0/en unknown
- 2017-02-03 ZA ZA2017/00883A patent/ZA201700883B/en unknown
- 2017-02-17 CO CONC2017/0001601A patent/CO2017001601A2/es unknown
- 2017-02-27 PH PH12017500348A patent/PH12017500348A1/en unknown
- 2017-03-07 DO DO2017000058A patent/DOP2017000058A/es unknown
- 2017-03-09 CL CL2017000587A patent/CL2017000587A1/es unknown
-
2019
- 2019-01-15 CY CY20191100049T patent/CY1121369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| MX2016015743A (es) | Compuestos de ciclopropilamina como inhibidores de histona demetilasa. | |
| CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| GEP20217239B (en) | Pharmaceutical composition | |
| CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
| BR112016012146A8 (pt) | derivados de aminopiridina como inibidores de quinase da família tam | |
| DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| BR112017000456A2 (pt) | composições antivirais tópicas e métodos de uso das mesmas | |
| EP4169508B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ALPELISAB | |
| MX370900B (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas. | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| MX2017007377A (es) | Compuestos organicos. | |
| BR112017028549A2 (pt) | derivados de pirimidina como inibidores de btk e usos dos mesmos | |
| GEP20217240B (en) | Pharmaceutical composition | |
| MX2017007371A (es) | Compuestos antibacterianos que tienen un amplio espectro de actividad. | |
| BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
| GT201600252A (es) | Derivados de naftiridinadiona |